Precision BioSciences, Inc.
DTIL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.01 | -0.01 | 0.19 |
| FCF Yield | -225.46% | -205.38% | -46.92% | -3.84% |
| EV / EBITDA | -2.20 | 1.35 | 0.92 | -14.79 |
| Quality | ||||
| ROIC | -21.32% | -32.80% | -61.33% | -22.22% |
| Gross Margin | 100.00% | 83.06% | 64.12% | 100.00% |
| Cash Conversion Ratio | -8.15 | 1.37 | 0.41 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 39.88% | -25.01% | 1.10% | 73.19% |
| Free Cash Flow Growth | 32.06% | -76.05% | -194.62% | 81.98% |
| Safety | ||||
| Net Debt / EBITDA | -4.13 | 2.67 | 2.59 | 6.64 |
| Interest Coverage | -14.68 | -19.61 | -90.34 | -298.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.19 | 0.00 |
| Cash Conversion Cycle | 9.02 | -35.37 | 290.14 | 1.54 |